Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-Bioartificial Liver

被引:15
|
作者
Nibourg, Geert A. A. [1 ,2 ]
Hoekstra, Ruurdtje [1 ,2 ]
van der Hoeven, Tessa V. [1 ,2 ]
Ackermans, Mariette T. [3 ]
Hakvoort, Theodorus B. M. [2 ]
van Gulik, Thomas M. [1 ]
Chamuleau, Robert A. F. M. [2 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Endocrinol, NL-1105 Amsterdam, Netherlands
关键词
AMC-BAL; fulminant hepatic failure; liver assist device; liver support; toxicity; CELL-LINE; HEPATOCYTE FUNCTION; GENE-EXPRESSION; HEPG2; CELLS; SERUM; OVEREXPRESSION; CYTOTOXICITY; METABOLISM; DEVICES; GROWTH;
D O I
10.1111/liv.12090
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims The AMC-bioartificial liver loaded with the human hepatoma cell line HepaRG as biocomponent (HepaRG-AMC-BAL) has recently proven efficacious in rats with acute liver failure (ALF). However, its efficacy may be affected by cytotoxic components of ALF plasma during treatment. In this study, we investigated the effects of ALF-plasma on the HepaRG-AMC-BAL. Methods HepaRG-AMC-BALs were connected to the blood circulation of rats with total liver ischaemia, either during the first 5h after induction of ischaemia (mild ALF group), or during the following 10h (severe ALF group). After disconnection, the BALs were assessed for cell leakage, gene transcript levels, ammonia elimination, urea production, cytochrome P450 3A4 activity, apolipoprotein A 1 production, glucose and amino acid metabolism. Results Cell leakage increased 2.5-fold in the severe ALF group, but remained limited in all groups. Hepatic gene transcript levels decreased (max 40-fold) or remained stable. In contrast, hepatic functions increased slightly or remained stable. Particularly, urea production increased 1.5-fold, with a concurrent increase in arginase 2 transcription and arginine consumption, with a trend towards reduced conversion of ammonia into urea. The amino acid consumption increased, however, the net glucose consumption remained stable. Conclusions The HepaRG-AMC-BAL retains functionality after both mild and severe exposure to ALF plasma, but urea production may be increasingly derived from arginase 2 activity instead of urea cycle activity. Nevertheless, the increase in cell leakage and decrease in various hepatic transcript levels suggest that a decrease in hepatic functionality may follow upon extended exposure to ALF plasma.
引用
收藏
页码:516 / 524
页数:9
相关论文
共 50 条
  • [41] PLASMA CYTOKINE LEVELS IN PATIENTS WITH FULMINANT HEPATIC-FAILURE (FHF) TREATED WITH A BIOARTIFICIAL LIVER (BAL)
    ROSEN, HR
    LEBOW, LT
    LEPAGE, E
    VIERLING, JM
    DEMETRIOU, AA
    GASTROENTEROLOGY, 1994, 106 (04) : A971 - A971
  • [42] Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure
    Demetriou, AA
    Brown, RS
    Busuttil, RW
    Fair, J
    McGuire, BM
    Rosenthal, P
    Esch, JSA
    Lerut, J
    Nyberg, SL
    Salizzoni, M
    Fagan, EA
    de Hemptinne, B
    Broelsch, CE
    Muraca, M
    Salmeron, JM
    Rabkin, JM
    Metselaar, HJ
    Pratt, D
    De La Mata, M
    McChesney, LP
    Everson, GT
    Lavin, PT
    Stevens, AC
    Pitkin, Z
    Solomon, BA
    ANNALS OF SURGERY, 2004, 239 (05) : 660 - 667
  • [43] A reliable graded acute liver failure model in rats: treatment with internal bioartificial liver
    Qing-Xiang Xu
    Hepatobiliary Surgery Institute of Nanjing
    Biochemistry Department of Nanjing University
    Hepatobiliary&PancreaticDiseasesInternational, 2004, (02) : 254 - 258
  • [44] The development of a new bioartificial liver and its application in 12 acute liver failure patients
    Yi-Tao Ding Yu-Dong Qiu Zhong Chen Qing-Xiang Xu Qing Tang De-Cai Yu Hepatobiliary Surgery Department
    Hepatobiliary Surgery Institute of Nanjing
    World Journal of Gastroenterology, 2003, 9 (04) : 829 - 832
  • [45] Liver transplantation for acute hepatic failure
    Wu, YM
    Ho, MC
    Hu, RH
    Ko, WJ
    Yang, PM
    Lai, MY
    Lee, PH
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (08) : 2226 - 2227
  • [46] Liver transplantation for acute hepatic failure
    de Rave, S
    Tilanus, HW
    Hop, WCJ
    JOURNAL OF HEPATOLOGY, 2000, 32 : 50 - 50
  • [47] Hepatic encephalopathy in acute liver failure
    Blei, A. T.
    Hepatic Encephalopathy and Nitrogen Metabolism, 2006, : 433 - 441
  • [48] Liver transplantation for acute hepatic failure
    Yeganehfar, W
    Wamser, P
    Rockenschaub, S
    Schindl, M
    Mittlbock, M
    Eisenhuber, E
    Madl, C
    Langle, F
    Berlakovich, G
    Muhlbacher, F
    Steininger, R
    WIENER KLINISCHE WOCHENSCHRIFT, 1998, 110 (16) : 570 - 578
  • [49] Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation
    Samuel, D
    Ichai, P
    Feray, C
    Saliba, F
    Azoulay, D
    Arulnaden, JL
    Debat, P
    Gigou, M
    Adam, R
    Bismuth, A
    Castaing, D
    Bismuth, H
    TRANSPLANTATION, 2002, 73 (02) : 257 - 264
  • [50] Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device
    Donini, A
    Baccarani, U
    Risaliti, A
    Degrassi, A
    Bresadola, F
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (04): : 1102 - 1104